SEARCH

SEARCH BY CITATION

Abstract

  1. Top of page
  2. Abstract
  3. References

The economic assessment of liver transplantation is complex and involves the cost of the transplant procedure, the cost of alternative treatments and the positive economic contribution of successful outcomes. The one-year survival rates are currently in the order of 80–90% for elective transplants and 60–75% for emergency transplantation. The average cost of a liver transplant operation in the UK is between £32 000 and £45 000. Factors which have a major influence on costs are aetiology, patient status at the time of transplantation, retransplantation and duration of hospital stay. Rejection episodes, renal impairment and surgical complications are of intermediate importance. The cost of transplantation must be balanced against the cost of alternative treatments that would be required if the patient were not transplanted and the positive economic benefit derived from excellent rehabilitation in the majority of recipients.

Footnotes
  1. Series Editors for Clinical Economics Reviews: K. Bodger, M. Daley & R.V. Heatley

References

  1. Top of page
  2. Abstract
  3. References
  • 1
    Dean M Is your treatment economic, effective, efficient? Lancet 1991; 11: 4801.
  • 2
    Bodger K, Daly MJ, Heatley RV, Williams DRR Clinical economics in gastroenterology. Aliment Pharmacol Ther 1996; 10: 55–61.
  • 3
    Ramage JK, Wong P, Hayllar K, Williams R Overall survival results; quality of life and management. In: Williams R, Portmann B, Tan K-C, eds. The Practice of Liver Transplantation. London: Churchill Livingstone, 1995: 259–70.
  • 4
    Evans RW, Manninen DL, Dong FB An economic analysis of liver transplantation. Gastroenterol Clin N Am 1993; 22: 451–73.
  • 5
    McPeake JR & Portmann B Hepatic malignancy, Budd–Chiari syndrome and space-occupying conditions. In: Williams R, Portmann B, Tan K-C, eds. The Practice of Liver Transplantation. London: Churchill Livingstone, 1995: 57–71.
  • 6
    Penn I Hepatic transplantation for primary and metastatic cancer of the liver. Surgery 1991; 11: 72634.
  • 7
    McPeake JR, O'Grady JG, Zaman S, et al. Liver transplantation for primary hepatocellular carcinoma: tumour size and number determines outcome. J Hepatol 1993; 11: 22634.
  • 8
    O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B reinfection after orthotopic liver transplantation: serological and clinical implications. J Hepatol 1992; 11: 104.
  • 9
    Samuel D & Bismuth H Liver transplantation for hepatitis B. In: Lake JR, ed. Advances in liver transplantation. Gastroenterol Clin N Am 1993; 11: 27183.
  • 10
    Shaw BW Jr, Wood RP, Gordon RD, Iwatsuki S, Gillquist WP, Starzl TE Influence of selected patient variables and operative blood loss on six-month survival following liver transplantation. Semin Liver Dis 1985; 11: 38593.
  • 11
    Kim WR, Therneau TM, Evans RW, Steers JL, Wiesner RH, Dickson ER Can resource utilization and quality of life post-transplant be predicted based on preoperative variables? Hepatology 1996; 11: 301A (Abstract).
  • 12
    Brown RS, Lake JR, Ascher NL, Emond JC, Roberts JP Predictors of the cost of liver transplantation. Hepatology 1996; 11: 299A (Abstract).
  • 13
    Spanier TB, Klein RD, Nasraway SA, et al. Multiple organ failure after liver transplantation. Crit Care Med 1995; 11: 46673.
  • 14
    Muto P, Freeman RB, Haugg CE, Lu A, Rohrer RJ., 1994; 57: 306–8 (Letter).
  • 15
    Aboulijoud MS, Baliad P, Hocking N, et al. Managed care strategies in liver transplantation: Is there a clinical benefit? Hepatology 1996; 11: 243A (Abstract).
  • 16
    Buroughs AK, Blake J, Thorne S, Else M, Rolles K Comparative hospital costs of liver transplantation and the treatment of complications of cirrhosis. A prospective study. Eur J Gastroenterol Hepatol 1992; 4: 123–8.
  • 17
    Williams R & Tan KC Requirement of staff and facilities. In: Williams R, Portmann B, Tan K-C, eds. The Practice of Liver Transplantation. London: Churchill Livingstone, 1995: 3–10.
  • 18
    McKenna M, Alexander G, Jones M, Hutton J Economic analysis of tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Eur Hosp Pharm 1996; 11:
  • European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet
    1994; 11: 4238.
  • 20
    Staschak S, Wagner S, Block G, et al. A cost comparison of liver transplantation with FK506 or CyA as the primary immunosuppressive agent. Transplant Proc 1990; 11 (Suppl. 1): 479.
  • 21
    Lake JR, Gorman KJ, Esquivel CO, et al. The impact of immunosuppressive regimens on the cost of liver transplantation—Results from the U.S. FK506 multicenter trial. Transplantation 1995; 11: 108995.
  • 22
    Ascher NL, Roberts JP, Lake JR The use of older donor livers is associated with increased cost of liver transplantation. Hepatology 1996; 11: 183A (Abstract).
  • 23
    Bonsel GJ, Klompmaker IJ, Essink-Bot ML, Habbema JDF, Slooff MJH Cost-effectiveness analysis of the Dutch liver transplantation programme. Trans Proc 1990; 11: 14814.
  • 24
    Emond JC, Aran PP, Whitington PF, Broelsch CE, Baker AL Liver transplantation in the management of fulminant hepatic failure. Gastroenterology 1989; 11: 15835.
  • 25
    Ascher NL, Lake JR, Emond JC, Roberts JP Liver transplantation for fulminant hepatic failure. Arch Surg 1993; 11: 67782.
  • 26
    Castells A, Salmeron JM, Navasa M, et al. Liver transplantation for acute liver failure: analysis of applicability. Gastroenterology 1993; 11: 5328.
  • 27
    Munoz SJ, Moritz MJ, Martin P, Jarrell BE, Maddrey WC Liver transplantation for fulminant hepatocellular failure. Trans Proc 1993; 11: 17735.
  • 28
    Mirza DF, Mohamed R, Mutimer DJ, McMaster P Timing and candidacy for transplantation in acute liver failure: the European experience. Liver Transplant Surg 1995; 11: 1826.
  • 29
    O'Grady JG, Wendon J, Tan KC, et al. Liver transplantation after paracetamol overdose. Br Med J 1991; 11: 2213.
  • 30
    Sussman NL, Gislason G, Conlin CA, Kelly JH The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Organs 1994; 11: 3906.
  • 31
    Ellis AJ, Wendon J, Hughes R, et al. The extracorporeal liver assist device in acute liver failure: design and testing of a controlled trial protocol. Hepatology 1996; 11: 144651.
  • 32
    Demetriou AA, Rozga J, Podesta, E et al. Early clinical experience with a hybrid bioartificial liver. Scand J Gastroenterol 1995; 11 (Suppl.): 1117.
  • 33
    Lowe D, O'Grady J, McEwen J, Williams R Quality of life following liver transplantation: a preliminary report. J R Coll Physicians 1990; 11: 4350.
  • 34
    Tarter RE, Switala J, Plail J, Havrilla J, Van Thiel DH Severity of hepatic encephalopathy before liver transplantation is associated with quality of life after transplantation. Arch Intern Med 1992; 11: 2097101.
  • 35
    Stewart SM, Hiltebeitel C, Nici J, et al. Neuropsychological outcome of pediatric liver transplantation. Pediatrics 1991; 11: 36776.